46 Comments

Forgive my language but where the Hell is the Institutional Review Board that is supposed to oversee human trials? I’m on the IRB at my institution and I take it really seriously. We’re constantly asking experts in other fields for feedback and we send almost every proposal back for more work. We also refuse even more and some of those are for things like questionaries that are unnecessarily invasive. This is 25 times worse. Where on earth is the IRB?????

Expand full comment

I know exactly what you mean. When I was a faculty member at Minnesota Duluth, teaching research design to psychology students, I had an IRB reject a student's undergrad research proposal on the grounds that he had not justified why the subjects listened to a seven minute musical piece in the intervention stage! As a public health faculty member at Purdue, I constantly had to remind our IRB that the Common Rule definition of a *human subject* does not include organizations, and hence studies using organizational level data alone were outside their scope. Most IRBs I have encountered fail, if anything, by being TOO cautious - and yet this was an egregious error.

Could it be funding sources? The Common Rule processes are only legally applicable to federally funded research or privately funded work where the funding contract demands compliance. That doesn't excuse the ethics of the projects, but may point to a hole in the institution's specific policies for oversight of a project.

Let's face it - the maneuvers Anthony Fauci and NIAID made to get around US limitations on gain-of-function research by laundering money through an NGO to a foreign lab in a country with no such limits clearly indicates that there are those who are willing to go to great links to exploit loopholes in research ethics policies.

Expand full comment

I looked up the trial. It was privately funded.

Expand full comment

That's how everything is in corporate America today. And doctors are controlled by big Pharma and Wall Street that don't care about competence. Incompetence and corruption go hand in hand. That is because incompetence necessitates cheating and corruption, and then the cover up.

Expand full comment

This is standard practice, but something not disclosed. In Vinay's example, the control arm was at least a medication. In most non-oncology trials, the control arm is a placebo. I doubt the average community-based clinician knows this. Instead, people get duped into thinking that the experimental drug is showing itself to be safer and more effective than existing treatments. However, the word choice unethical is emotionally loaded. It caught my attention; however, it is important to raise awareness of how studies are designed and say it in a way so that everyday people understand this concept.

Expand full comment

Perhaps more medical media coverage with the flawed studies and doctors promoting them would start to turn the Titanic around. However, pharmaceutical companies, FDA and institutions seem unlikely to heed this until it hits them where it counts. Thanks for the report and here’s hoping that medical research and care returns to the science based model we used to follow.

Expand full comment

Sadly patients who participate are not aware the they are not receiving the usual standard of care.

Expand full comment

Totally shocking. Hippocrates would be turning in his grave😢

Expand full comment

What's missing from this rant is that some patients don't want chemo (docetaxel, cabazitaxel) or 2nd line chemo. The point of the trial was to have other options. This from JPM-"We view cabo+atezo as a great chemo-sparing/delaying option in 2L mCRPC, providing significant optionality in a wide patient

population. The TKI-ICI combo is also a great option for the community setting, and we point to good feedback from KOLs"........Key Opinion Leaders...meaning top doctors in the mCRPC setting

Expand full comment

You’ve identified the exact reason why there’s no excuse not to do a study of vaccinated vs non vaccinated. Some people don’t want the vaccines.

Expand full comment

Also many people won't choose chemo. Look at JPM's data. Of mCRPC patients following NHT only 13% chose chemo. A full 33% chose another NHT. That is almost triple the number that choose chemo. And Atezo Cabo beat 2nd line NHT.

Yet those critical of the control (NHT) in this trial are projecting everyone chooses chemo. Far from it.

Expand full comment

I agree. Vinay's unedited writing on his social media is often full of grammatical errors. But that's not why he has lost credibility.

Expand full comment

Last one out please turn off the lights.

Medical science is dead.

Expand full comment

I think it would be appropriate to contact the Ethics committees that approved these studies and the Heads of their institutions to ask them to review their process of reviewing studies to ensure that they are upholding the requirement for best available therapy in the control arm.

Expand full comment

Agreed! When Vinay highlights these control arm issues, I always wonder where the hell the REB was. They are supposed to have decent representation of the various specialties and surely anyone can ask whether the control arm is standard of care.

Expand full comment

Interesting thought. Do you have any ideas about who to target if you want to change this aspect of clinical trial design? Imagine there was a requirement that the comparator is the best available treatment. Would you try to influence the public, individual IRBs, Congress, or government agencies? And is this possible to achieve in terms of drugs getting accelerated approval?

Expand full comment

Just another chapter in the annals of pharma/academy collusion in pursuit of the big bucks in research grants and subsequent pharma profits. Sometimes it is a little hard to follow the narrative because of all the abbreviations. I wish that authors and commentors would spell out the terms the first time they are mentioned in an article or comment and then use the abbreviations in the rest of the text. Thanks for shedding light on this tactic of setting up a "straw man" in the control arm of a study.

Expand full comment

Could a requirement be built into informed consent documentation that states that the participant must be aware of the treatment he would receive if he were not a participant in the study? I'm saddened to think that the participants' oncologists didn't counsel them more explicitly about their options; maybe if trial PIs were required to tell patients exactly what they were forgoing, fewer would opt in, and trials with this type of ethical problem would die out. It feels like a clunky requirement to write and enforce, though.

Expand full comment

In clinical trials, randomized clinical trials are generally blinded. Not always, but usually. In other words, no one knows who is in the control versus experimental group. A friend, seeking to joining an immunotherapy study for lung cancer, was surprised to learn she might not get the experimental drug. Before starting, she asked the doctor and learned she wouldn't receive it. Surprisingly, the principal investigator honestly answered that she would not. Raising awareness of this is crucial to inform people about this issue.

Expand full comment

I meant something a little bit different: that the participant should know what the control group gets, and whether it's different from what he would get if he were not in the study at all. Now, maybe that person would be randomized into the experimental arm, but he should know when he thinks about entering the study whether being in the control arm would be worse than getting the standard of care from his regular doctor.

You are right, though, that trial participants should know whether they're entering an open-label study, a study with true randomization, or some other variation... If they are in an RCT and don't understand that they may not get the experimental treatment, then they obviously don't understand what they're consenting to. In an era when industry and academia are partnering to widen the range of individuals who can "consent" (see: https://doi.org/10.1186/s13063-024-07944-x), it's disturbing that the consent procedures for average people are not adequate.

Expand full comment

Thanks for clearing that up. Is there a way to find out more about you and your interests?

Expand full comment

I'm just a regular person :-) I used to read Dr. Prasad's work when he published at MedPage Today, and I found his book *Malignant* to be both informative and thought-provoking. I haven't read *Ending Medical Reversal,* but I've liked Dr. Cifu's pieces on this Substack a great deal.

Expand full comment

Are these “drs” in some kind of death cult? Sure seems like it. These last 4 years are eye opening and I wish it were all untrue

Expand full comment

Same thing Brandeis tried to do a 100 years ago: If the broad light of day could be let in upon men’s actions, it would purify them as the sun disinfects.

Thank God for Covid. It took away the veneer of trust I had in CDC/FDA/most Doctors. Who knows, maybe I'd be on Ozempic were it no for Covid opening my eyes (actually, I wouldn't because I'm not *that* stupid) So while I'm not an SME and have no idea what the specifics are, it reads like par for the course. If NIH and CDC and FDA behave unethically, why WOULDN'T everyone else?

Expand full comment

Forgive my ignorance since I'm not an oncologist. Was the menu of what's considered best available therapy available at the majority of the study sites where this trial was conducted?

Expand full comment

Thank you.

"The trial should be designed such that if your father was assigned to the control arm, you would be reassured knowing he was getting the best proven care absent the experimental drug."

If the Hippocratic Oath were re-written, I'd include: Never give a treatment that you would not give to your family, loved ones, or yourself.

It is a version of skin in the game. It is a heuristic that acts as a check on so-called science that increasingly is scientism.

Expand full comment